Speakers - Sachs Associates

More documents

Recommendations

Info

CONTACT Kostas Alevizopoulos PhD Chief Executive Officer ADDRESS APIM Therapeutics AS c/o NTNU Tech Transfer AS Sem Sælandsvei 14 Kjemiblokk 1, 3etg N-7491 Trondheim Norway TELEPHONE +41 78 752 7002 EMAIL contact@apimtherapeutics.com kalevizo@apimtherapeutics.com YEAR FOUNDED Founded in 2009 as a spin out from the Norwegian University of Science and Technology in Trondheim (NTNU), Norway. APIM Therapeutics AS www.apimtherapeutics.com FINANCIAL SUMMARY Venture Capital Financed. Current investors include: • Sarsia Seed • Birk Venture • Ro Invest • Norsk Innovasjonskapital AS COMPANY PROFILE APIM Therapeutics AS is a Norwegian biotech company set to develop and commercialize novel anti-cancer therapies potentiating chemotherapy-induced responses in cancer cells. We offer a unique physiological intervention point targeting a cellular “hub” protein called Proliferating cell Nuclear Antigen (PCNA). PCNA acts a master regulator of replication, repair, cell cycle control and apoptosis, ultimately controlling responses to pathological (cancer) and pharmacological (chemotherapy) stress in cells. ATX-101, the company’s current preclinical lead, features a novel PCNA-interacting Stress Switch Peptide Motif termed APIM. This motif, being incorporated in peptide sequence, interferes with several cellular defense systems dealing with stress resulting in both hypersensitivity to chemotherapy and direct induction of apoptosis in selected cancer cells. Overall, ATX-101 has shown potent preclinical efficacy including single agent activity and potentiation of the action of >15 clinical drugs in vitro (cisplatin, melphalan, bleomycin, cytarabine, decitabine, dasatinib, vorinostat, bortezomib and others) as well as proof-of-efficacy in animal models of blood cancer and solid tumor indications. Currently, ATX-101 is being developed as a novel candidate drug for various oncology indications. MANAGEMENT Kostas Alevizopoulos Ph.D., Chief Executive Officer Marit Otterlei Ph.D., Chief Scientific Officer t back :: next u WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS
CONTACTS Dr Bassam Damaj Chairman, President & CEO Ed Cox VP Corporate Development & IR ADDRESS 6330 Nancy Ridge Dr., Suite 103 San Diego, CA 92121 U.S.A. TELEPHONE (858) 222-8041 FAX (858) 866-0482 EMAIL bdamaj@apricusbio.com ecox@apricusbio.com YEAR FOUNDED 1987 Apricus Biosciences, Inc. www.apricusbio.com FINANCIAL SUMMARY NASDAQ: APRI Shares Out: 19.6M* Fully-diluted Shs: 22M* Float: 16M* Cash position $10.2M* Share-price $5.26** Marketcap ~$105M** Ave. Daily volume ~320k** 2010 Revenues ~$5M *As of March 31, 2011, **As of June 24, 2011 COMPANY PROFILE Apricus Bio (Nasdaq:APRI) is a pharmaceutical company that develops and markets innovative treatments that help large patient populations across numerous, high-demand therapeutic classes. The Company has four approved products and has developed a strong pipeline of multiple late-stage product opportunities. With commercial operations in both the U.S. and Europe (France), Apricus Bio generates revenues and growth from sales of its commercial products and by out-licensing, in certain territories, its pipeline products and NexACT® technology. Apricus Bio’s growth strategy is to acquire, develop, and commercialize new products through strategic partnerships. The Company currently has commercial partnerships with multiple large pharmaceutical companies including Novartis, Abbot Laboratories, Takeda, Sandoz, Warner Chilcott and Bracco, and co-promotes multiple products in France. Apricus Biosciences is headquartered in San Diego, CA and is publicly traded on the NASDAQ under the ticker symbol APRI. MANAGEMENT Dr Bassam Damaj, Chairman, President and Chief Executive Officer Steve Martin, Senior Vice President and Chief Financial Officer Edward Cox, Vice Corporate Development and Investor Relations Randy Berholtz, Executive Vice President, General Counsel and Secretary t back :: next u WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS
Page 1 and 2: B I O T E C H I N E U R O P E I N V
Page 3 and 4: Events Diary For regular updates, s
Page 5 and 6: Speakers Alexey Eliseev, Managing D
Page 7 and 8: Speakers Blake M. Paterson, Co-Foun
Page 9 and 10: Speakers David Slack, Head of Corpo
Page 11 and 12: Speakers Frank Grams, VP, Head Alli
Page 13 and 14: Speakers Iain Buchanan, CEO, NOXXON
Page 15 and 16: Speakers Juhani Lahdenperä, CEO, H
Page 17 and 18: Speakers Marcel Zwaal, CBO, DCPrime
Page 19 and 20: Speakers Paul Higham, Managing Dire
Page 21 and 22: Speakers Richard Goodfellow, CEO, S
Page 23 and 24: Speakers Søren Moller, Managing In
Page 25 and 26: CONTACT Robert F Burns, PhD Chief E
Page 27 and 28: CONTACTS Rostislav Raykov Chief Exe
Page 29: CONTACTS Vincent Charlon PhD, CEO Z
Page 33 and 34: CONTACT Carina Schmidt Chief Execut
Page 35 and 36: CONTACT Mr Richard Godfrey Chief Ex
Page 37 and 38: CONTACTS Tom Kronbach, PhD Chief Ex
Page 39 and 40: CONTACTS Andreas Caduff, PhD Chief
Page 41 and 42: CONTACTS Dr Blake Paterson Co-Found
Page 43 and 44: CONTACT Wolfgang Kintzel Chief Exec
Page 45 and 46: CONTACT Mike Romanos PhD Chief Exec
Page 47 and 48: CONTACT Harry Welten, MBA Chief Fin
Page 49 and 50: CONTACT Barbara Stiefel Office Mana
Page 51 and 52: CONTACTS Ana Martinez Assistant Jua
Page 53 and 54: CONTACTS Dr Rudi D Neirinckx Chief
Page 55 and 56: CONTACT Martin Bonde, PhD, BComm Ch
Page 57 and 58: CONTACT Benedikt Timmerman Chief Ex
Page 59 and 60: CONTACT Malcolm Weir Chief Executiv
Page 61 and 62: CONTACTS Mr Paul Higham Chief Execu
Page 63 and 64: CONTACTS Kevin FitzGerald Chief Ope
Page 65 and 66: CONTACT Roel Q. J Schaapveld, PhD,
Page 67 and 68: CONTACT Maaike Vogelezang Managemen
Page 69 and 70: CONTACT Tom Johnston Chief Executiv
Page 71 and 72: CONTACTS Aaron Powers President Dav
Page 73 and 74: CONTACTS General and Media Contact
Page 75 and 76: CONTACTS Martin Welschof Chief Exec
Page 77 and 78: CONTACTS Carlos Buesa Chief Executi
Page 79 and 80: CONTACTS Nick McCooke Chief Executi
Page 81 and 82:
CONTACT Dr Erik Buntinx Chief Execu
Page 83 and 84:
CONTACT Michael Altorfer, Ph.D. Hea
Page 85 and 86:
CONTACT Matthew B. Lehman Chief Ope
Page 87 and 88:
ADDRESS Otto-Hahn-Strasse 15 D- 442
Page 89 and 90:
CONTACT Dr Roman Schenk Chief Execu
Page 91 and 92:
CONTACTS Dr Hans Fliri Chairman Sim
Page 93 and 94:
CONTACTS Dr Raúl Insa Chief Execut
Page 95 and 96:
CONTACT Dr Johanna Holldack, MD Chi
Page 97 and 98:
CONTACT Eduardo Bravo (speaker) Man
Page 99 and 100:
CONTACTS Piers Morgan Chief Financi
Page 101 and 102:
CONTACT Jakob Knudsen Chief Executi
Page 103 and 104:
CONTACTS Dr Sonja Reingruber Chief
Page 105 and 106:
Supporting Organisations Citigate D
Page 107 and 108:
Supporting Organisations Life Scien
Page 109 and 110:
Supporting Organisations Swiss Biot
Page 111 and 112:
Supporting Organisations Torreya Pa
Page 113:
B I O T E C H I N E U R O P E I N V
show all

Speakers - Sachs Associates

Create successful ePaper yourself

Delete template?

Save as template?